Vaximm
Clinical-stage biotechnology company developing an oral T‑cell immunotherapy platform that uses a genetically modified eukaryotic oral delivery vector to target gut-associated lymphoid tissue and elicit systemic cytotoxic T‑cell responses for oncology indications. The organization has advanced candidates through Phase I/II clinical studies, has published clinical data, and pursues partnerships and licensing to support development and commercialization.
Industries
Nr. of Employees
small (1-50)
Vaximm
Technologiepark Basel, Hochbergerstrasse 60c, CH-4057 Basel, Switzerland
Patents
Products
VXM01
An oral T‑cell immunotherapy candidate that delivers genetic sequences to induce T‑cell responses against VEGFR2, evaluated in Phase I/II oncology trials including glioblastoma and pancreatic cancer.
VXM01
An oral T‑cell immunotherapy candidate that delivers genetic sequences to induce T‑cell responses against VEGFR2, evaluated in Phase I/II oncology trials including glioblastoma and pancreatic cancer.
Services
Collaborative design and execution of early‑phase oncology trials, including combination regimens with checkpoint inhibitors and external pharma partners.
Out‑licensing and strategic licensing arrangements to third parties for development and commercialization in defined territories.
Collaborative design and execution of early‑phase oncology trials, including combination regimens with checkpoint inhibitors and external pharma partners.
Out‑licensing and strategic licensing arrangements to third parties for development and commercialization in defined territories.
Expertise Areas
- Oral immunotherapy development
- T‑cell focused oncology immunotherapy
- Early‑stage clinical trial management (Phase I/II)
- Preclinical immunology and vaccine development
Key Technologies
- Genetically modified eukaryotic oral delivery vectors
- GALT / Peyer’s patch targeting
- Antigen‑specific CD8+ and CD4+ T‑cell activation
- Platform modular 'plug-and-play' antigen design
News & Updates
Announcement of a non‑binding term sheet to explore an exclusive global licensing agreement for the lead oral immunotherapy candidate, including potential upfront and milestone payments.
Announcement of appointment of the inventor of the core technology as Chief Medical Officer to guide clinical development of the oral T‑cell activator platform.
Final data released from an open‑label Phase 2a clinical trial assessing safety and tolerability of the oral T‑cell immunotherapy in combination with a PD‑L1 inhibitor in recurrent glioblastoma.
Received orphan designation from the European Commission and the US FDA for the treatment of glioblastoma.
Founded in 2008 as a spin‑out from academic research at UC San Diego to develop oral T‑cell immunotherapy technology.
Initiated a first‑in‑human Phase I dose escalation study for the lead candidate in pancreatic cancer patients.
Announcement of a non‑binding term sheet to explore an exclusive global licensing agreement for the lead oral immunotherapy candidate, including potential upfront and milestone payments.
Announcement of appointment of the inventor of the core technology as Chief Medical Officer to guide clinical development of the oral T‑cell activator platform.
Final data released from an open‑label Phase 2a clinical trial assessing safety and tolerability of the oral T‑cell immunotherapy in combination with a PD‑L1 inhibitor in recurrent glioblastoma.
Received orphan designation from the European Commission and the US FDA for the treatment of glioblastoma.
Founded in 2008 as a spin‑out from academic research at UC San Diego to develop oral T‑cell immunotherapy technology.
Initiated a first‑in‑human Phase I dose escalation study for the lead candidate in pancreatic cancer patients.